Developer docs
API playgroundTry for free, no card

Search company profiles

LiMM Therapeutics

Full company profile

uuid00036lx

Namestring
LiMM Therapeutics
Websiteurl
limmtx.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

LiMM Therapeutics is a Paris-based preclinical biopharmaceutical company founded in 2017 that develops therapeutics targeting molecular cross-talk between neuronal and innate lymphoid cells for immune-mediated diseases.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biopharmaceutical development, immunology therapeutics, drug discovery, innate lymphoid cells, neuro-immune research
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LiMM Therapeutics is a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells to develop novel therapeutics. The company's work targets neuro-immune interactions for the treatment of inflammatory and immune-related diseases, operating in the early-stage research and drug discovery domain.

Differentiator
Functional benefit
Problem solved
No data
Peers10 records
TypeDirect peer
Description

INmune Bio focuses on innate immune modulation to treat neurodegenerative and neuroinflammatory diseases. Its mechanism emphasis on innate immunity parallels LiMM's innate lymphoid cell approach in CNS indications.

TypeBroad incumbent
Description

Theravance Biopharma develops therapeutics including CNS and immunology programs. It is comparable as a biopharma with CNS pipeline presence and broader immunology expertise relevant to LiMM's innate-immune CNS approach.

TypeDirect peer
Description

Alector develops immuno-neurology therapies targeting neurodegenerative diseases by modulating microglial and innate immune function in the brain. It is the closest publicly listed peer to LiMM's neuronal-immune mechanism thesis.

TypeDirect peer
Description

reMYND develops therapeutics targeting neurodegeneration, including Alzheimer's and Parkinson's, with an emphasis on restoring neuronal protein homeostasis. It is comparable as a European early-stage CNS-focused biotech.

TypeRegional player
Description

GenSight Biologics is a Paris-based clinical-stage biotech developing gene therapies for CNS and ophthalmologic neurodegenerative diseases. It is comparable as a French preclinical/early-clinical CNS therapeutics peer.

TypeEmerging player
Description

LAVA Therapeutics engineers innate-like gamma-delta T cells and bispecific antibodies for cancer and immunology. Its focus on innate lymphoid lineage biology overlaps conceptually with LiMM's ILC mechanism, though its indication focus is oncology.

TypeDirect peer
Description

Confo Therapeutics is a Belgian biotech developing GPCR-targeting therapeutics for CNS and metabolic disorders. It is comparable as a European early-stage CNS biopharma with mechanistic differentiation.

TypeBroad incumbent
Description

Ipsen is a major French specialty pharmaceutical company with a meaningful neuroscience and neurotoxin franchise. It is comparable as an established Paris-based pharma that anchors the local CNS commercial ecosystem.

TypeEmerging player
Description

Egle Therapeutics is a Paris-based immuno-oncology biotech focused on regulatory T cells and immune biology. It is comparable as a French early-stage biotech built around novel lymphoid immune cell biology.

TypeDirect peer
Description

Cortexyme develops therapeutics targeting innate immune pathways in the brain for Alzheimer's disease and other neurodegenerative conditions. It is comparable as a CNS-focused biotech leveraging immune-system biology.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LiMM Therapeutics

Biopharmaceutical Therapeuticslimmtx.com

LiMM Therapeutics is a Paris-based preclinical biopharmaceutical company founded in 2017 that develops therapeutics targeting molecular cross-talk between neuronal and innate lymphoid cells for immune-mediated diseases.

LiMM Therapeutics firmographics

Firmographics
Name
LiMM Therapeutics
Website
https://limmtx.com
Company type
Private
Founded year
2017
Headcount range
11–50 employees
Short description
LiMM Therapeutics is a Paris-based preclinical biopharmaceutical company founded in 2017 that develops therapeutics targeting molecular cross-talk between neuronal and innate lymphoid cells for immune-mediated diseases.
Ownership category
akta.pro rank

LiMM Therapeutics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Biopharmaceutical development
  • Immunology therapeutics
  • Drug discovery
  • Innate lymphoid cells
  • Neuro-immune research

Where LiMM Therapeutics is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

LiMM Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

LiMM Therapeutics product offering

Product offering

Core offering

LiMM Therapeutics is a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells to develop novel therapeutics. The company's work targets neuro-immune interactions for the treatment of inflammatory and immune-related diseases, operating in the early-stage research and drug discovery domain.

Differentiator

Problem solved

Functional benefit

Companies that use LiMM Therapeutics

Customer profile

Ideal customer profiles1 record

LiMM Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

LiMM Therapeutics competitors and assessment

Company assessment

Direct peers

  • INmune Bio: INmune Bio focuses on innate immune modulation to treat neurodegenerative and neuroinflammatory diseases. Its mechanism emphasis on innate immunity parallels LiMM's innate lymphoid cell approach in CNS indications.
  • Alector: Alector develops immuno-neurology therapies targeting neurodegenerative diseases by modulating microglial and innate immune function in the brain. It is the closest publicly listed peer to LiMM's neuronal-immune mechanism thesis.
  • reMYND: reMYND develops therapeutics targeting neurodegeneration, including Alzheimer's and Parkinson's, with an emphasis on restoring neuronal protein homeostasis. It is comparable as a European early-stage CNS-focused biotech.
  • Confo Therapeutics: Confo Therapeutics is a Belgian biotech developing GPCR-targeting therapeutics for CNS and metabolic disorders. It is comparable as a European early-stage CNS biopharma with mechanistic differentiation.
  • Cortexyme: Cortexyme develops therapeutics targeting innate immune pathways in the brain for Alzheimer's disease and other neurodegenerative conditions. It is comparable as a CNS-focused biotech leveraging immune-system biology.

Broad incumbents

  • Theravance Biopharma: Theravance Biopharma develops therapeutics including CNS and immunology programs. It is comparable as a biopharma with CNS pipeline presence and broader immunology expertise relevant to LiMM's innate-immune CNS approach.
  • Ipsen: Ipsen is a major French specialty pharmaceutical company with a meaningful neuroscience and neurotoxin franchise. It is comparable as an established Paris-based pharma that anchors the local CNS commercial ecosystem.

Regional players

  • GenSight Biologics: GenSight Biologics is a Paris-based clinical-stage biotech developing gene therapies for CNS and ophthalmologic neurodegenerative diseases. It is comparable as a French preclinical/early-clinical CNS therapeutics peer.

Emerging players

  • LAVA Therapeutics: LAVA Therapeutics engineers innate-like gamma-delta T cells and bispecific antibodies for cancer and immunology. Its focus on innate lymphoid lineage biology overlaps conceptually with LiMM's ILC mechanism, though its indication focus is oncology.
  • Egle Therapeutics: Egle Therapeutics is a Paris-based immuno-oncology biotech focused on regulatory T cells and immune biology. It is comparable as a French early-stage biotech built around novel lymphoid immune cell biology.

Market position

Customer concentration

LiMM Therapeutics social profiles

Digital presence

LiMM Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LiMM Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

LiMM Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LiMM Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LiMM Therapeutics

What does LiMM Therapeutics do?

LiMM Therapeutics is a biopharmaceutical company that harnesses the molecular cross-talk between neuronal and innate lymphoid cells to develop novel therapeutics. The company's work targets neuro-immune interactions for the treatment of inflammatory and immune-related diseases, operating in the early-stage research and drug discovery domain.

When was LiMM Therapeutics founded?

LiMM Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is LiMM Therapeutics based?

LiMM Therapeutics is headquartered in Paris, France, in the Europe region.

Who are LiMM Therapeutics's main competitors?

Direct peers on record are INmune Bio, Alector, reMYND, Confo Therapeutics and Cortexyme. Broad incumbents are Theravance Biopharma and Ipsen. GenSight Biologics is listed as a regional player. Emerging players are LAVA Therapeutics and Egle Therapeutics.

Does LiMM Therapeutics have an API?

No public API is recorded for LiMM Therapeutics.

What industry is LiMM Therapeutics in?

LiMM Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales